Forbes November 12, 2025
In one of the most consequential healthcare deals of the year, President Trump’s new drug-pricing pact with Eli Lilly and Novo Nordisk slashes the cost of blockbuster GLP-1 drugs like Wegovy and Zepbound, turning a luxury medicine into a mainstream benefit—and forcing Ro, Hims, Mochi Health, and other telehealth players to rethink their most lucrative business model.
A Populist Price Drop That Changes Everything
President Donald Trump’s latest “Most Favored Nation” drug-pricing deal has redrawn the weight-loss map.
In exchange for discounted list prices—around $245 a month under Medicare with a $50 copay—Eli Lilly and Novo Nordisk secured expanded federal coverage for obesity-related care starting in 2026.
It’s a steep fall from list prices that once topped $1,000, and a direct...
Today's Sponsors
Today's Sponsor